Aeon Respire

Aeon Respire is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for respiratory conditions, with a primary focus on Chronic Obstructive Pulmonary Disease (COPD). The company's lead therapeutic candidate, AEON-101, is a long-acting muscarinic antagonist (LAMA) formulated for inhaled administration to provide prolonged bronchodilation and symptom relief. Aeon Respire's development strategy centers on improving the efficacy and safety profiles of established drug classes to better serve patients with chronic lung diseases. Headquartered in Newport Beach, California, the company operates within the Alphaeon/Aeon ecosystem of life science ventures.